Bonnie leads Monograph Capital’s investments in MiroBio and has been a Principal at Monograph Capital, since August 2021. Her activities include sourcing, evaluation, deal execution and portfolio management of life science companies. Prior to joining Monograph Capital, Bonnie worked for four years at leading European VC firm, Forbion, where she was observer to the board of Inflazome, which was sold to Roche in 2020 for 450m USD plus milestone payments. Before that, she worked for a decade as an academic scientist in the fields of immunology, virology and stem cells at Oxford University and the University of Melbourne, publishing in top-tier academic journals. Bonnie earned her DPhil at Oxford.
Previously, Brandi was an Executive Assistant at TPG. She supported several leaders, including the Co-CEO, Jon Winkelried, TPG Senior Advisors Dr Fred Cohen, Edward Norton, and the Honorable William K. Reilly. Brandi began her career as an assistant working aboard M.Y. Silver Lining. She continued her career at the Santa Fe Film Festival, the Doha Film Institute in Qatar, and the 34th America’s Cup in San Francisco, before moving into private equity and venture capital.
Before co-founding Monograph Capital, Charles was CEO of Oxford Sciences Innovation, a £600m deep science venture firm formed in partnership with Oxford University. Charles is a technology entrepreneur and former public company CEO (Ticketmaster, Citysearch, Match.com). He serves on the board of Patagonia and was previously CEO of the Rhodes Trust in Oxford. Before that he was senior advisor to the Gordon & Betty Moore Foundation in San Francisco. He began his career at McKinsey & Company, where he was a Partner. Charles is a best-selling author on problem solving and is a member of The Nature Conservancy’s European Council for Global Conservation. Charles is a graduate of Harvard Business School, Boston University, and Oxford University, where he was a Rhodes Scholar.
Charlie joined Monograph Capital from Bain and Company, where he worked within the private equity advisory team, with a focus on the healthcare sector. He completed his medical training at Cambridge University and Oxford University prior to practicing at the Royal Free NHS Foundation Trust. Charlie also completed a Master of Public Health at Harvard University as a Fulbright Scholar, and contributed to research as a visiting scientist at the Harvard T.H. Chan School of Public Health.
Dr Fred Cohen is a Co-Founder and Senior Managing Director at Vida Ventures. Prior to Monograph, Fred was a Partner and founder of TPG Biotechnology, a life science focused investment effort from 2001-2016. From 1980 through 2014, Fred was at UCSF where he held various clinical responsibilities as a research scientist, an internist for hospitalized patients, a consulting endocrinologist, and as the Chief of the Division of Endocrinology and Metabolism. He received his B.S. degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil. in Molecular Biophysics from Oxford on a Rhodes Scholarship, his M.D. from Stanford, and his postdoctoral training and postgraduate medical training in Internal Medicine and Endocrinology at UCSF. Fred has been a member of the National Academy of Medicine since 2004 and the American Academy of Arts and Sciences since 2008.
Freddie is currently deployed in Ascend Gene and Cell Therapies, a Monograph Capital portfolio company, as Head of Corporate Development & Portfolio Manager. Ascend is a new gene and cell therapy manufacturing company pursuing a hybrid model of innovator, program accelerator and manufacturer. Previously, Freddie was a Partner at Syncona, a London based life science focussed venture firm, where he was involved in a number of investments, most notably Clade Therapeutics and Quell Therapeutics, where he held Board Observer roles. Prior to Syncona, he was a member of the Investment Team at the Wellcome Trust. Freddie holds a degree in Biochemistry from the University of Edinburgh.
Jaideep leads Portfolio Development at Human Immunology Biosciences (HIBio), a Monograph Capital portfolio company. He was most recently at Relay Therapeutics, a precision medicine company focused on oncology and rare genetic diseases, where he played a cross-functional role in R&D and strategy/BD. Before that, Jaideep was the first associate at Vida Ventures, and was involved in several of Vida’s investments, including Allogene (IPO), Asklepios BioPharmaceutical (acquired by Bayer), Oyster Point Pharma (IPO), and Pionyr Immunotherapeutics (acquired by Gilead). Jaideep completed his PhD at MIT in Biological Engineering, and holds a BS in Bioengineering from UCLA.
Jo has extensive experience supporting high net worth individuals within private equity, real estate, property and asset management. Prior to joining Monograph, Jo was EA to the Chairman & CEO at James Hambro & Partners. Previously, Jo worked at, Pacific Investments Plc and for a number of boutique property businesses.
Prior to Monograph Capital, Lucinda spent nearly a decade in a range of senior support roles at McKinsey in London. Most recently she has led operations at a successful UK start up. A seasoned, administrative professional, experienced in supporting c-suite executives and high-profile events, across a broad range of functions.
Luke is currently an attending physician-scientist at Memorial Sloan Kettering Cancer Center, where he cares for patients with brain tumors and prostate cancer. He leads a research group focused on the mechanisms of brain metastasis development and conducts prospective clinical trial work utilizing liquid biopsy approaches. Luke previously worked as a Senior Associate at Third Rock Ventures, a biotech-focused early stage venture firm. Luke studied Chemistry and Biochemistry at Memorial University. Luke pursued a D.Phil. in medical oncology at the University of Oxford as a Rhodes Scholar. After leaving Oxford, Luke obtained a medical degree at Yale, and completed his residency training in radiation oncology at the Harvard Radiation Oncology Program.
Melisa joined Monograph Capital from L.E.K. Consulting, where she was an Engagement Manager in the Healthcare and Life Sciences practice, working with biopharma, contract services organisations, diagnostics and research tools providers and investors. She was also a fellow with the World Economic Forum’s Healthcare Industries Platform. She completed her PhD in cancer biology focusing on DNA repair at the Francis Crick Institute, with multiple publications. She also holds a BSc in Biochemistry and MSc in Immunology, from Imperial College London.
Having qualified as an ICAEW Chartered Accountant and auditor from PwC’s Insurance and Investment Management practice, Nishat has worked in the finance teams of several not-for-profit organisations. Her most recent role was at the Coalition for Epidemic Preparedness Innovations. Nishat has an Investment Management Certificate from CFA UK and earned a Masters in Biochemistry at Oxford University.
Stephanie heads investor relations for Monograph Capital, overseeing existing LP relationships, fundraising, and strategic marketing efforts for the firm. Prior to joining Monograph in 2023, Stephanie spent over twelve years in business development and investor relations roles across sectors and asset classes including JP Morgan Private Bank, Communities Foundation of Texas, and Capview Partners, a $1.1 billion private equity real estate fund. Stephanie began her career as an Assistant District Attorney for Dallas County District Attorney’s Office in the White Collar Crime Division. Stephanie received her B.B.A in Accounting, M.S.A. in Accounting and her J.D. from Southern Methodist University in Dallas, Texas.
CEO of portfolio company, Human Immunology Bioscience.
Travis leads Monograph Capital’s investments in HIBio. Prior to Monograph Capital, Travis was a life sciences investor with Softbank Vision Fund, where he oversaw investments in Relay Therapeutics (NASDAQ: RLAY), Vividion Therapeutics (Acq by: BAYRY), Seer (NASDAQ: SEER), VIR (NASDAQ: VIR), Zymergen (NASDAQ: ZY), ElevateBio, Encoded Therapeutics, Insitro, Karius, and Collective Health. He was previously a Principal at Third Rock Ventures, and a consultant at McKinsey & Company. Travis is a gastroenterologist who worked with Northern communities in Canada. He trained in gastroenterology with a focus on inflammatory bowel diseases (IBD) at the University of Calgary and internal medicine at the University of Toronto. Travis studied immunology at Oxford University as a Rhodes Scholar and medicine at the University of Alberta.
CEO of portfolio company, Ascend Gene and Cell Therapies.
Tim leads Monograph Capital’s investments in Aviado and Ascend. Prior to Monograph Capital, Tim was co-founder and VP Operations for MiroBio. Tim has been a biotech investor and company-builder at Syncona, Third Rock Ventures, and Oxford Sciences, gaining experience across therapeutic modalities and geographies. He began his career at the Boston Consulting Group in London. Tim trained as a pharmacologist, with an undergraduate degree from University of Cambridge and DPhil from the University of Oxford.
